96 Spam-Free Article(s) Found
https://www.zacks.com/stock/news/2235686/dexcom-dxcm-rises-as-market-takes-a-dip-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2235686
Mar 04, 2024 - In the most recent trading session, DexCom (DXCM) closed at $122.30, indicating a +0.46% shift from the previous trading day.
zc:-537070262800573269
0
https://www.zacks.com/stock/news/2237878/community-health-cyh-cost-plus-drugs-unite-to-lower-drug-cost?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2237878
Mar 08, 2024 - Community Health (CYH) collaborates with Cost Plus Drug to reduce drug costs and shortages.
zc:7191212493598686268
0
https://www.zacks.com/stock/news/2242241/reasons-to-retain-dexcom-dxcm-stock-in-your-portfolio-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2242241
Mar 18, 2024 - DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
zc:-4566655126446093109
0
https://www.zacks.com/stock/news/2246003/has-dexcom-dxcm-outpaced-other-medical-stocks-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2246003
Mar 26, 2024 - Here is how DexCom (DXCM) and Anika Therapeutics (ANIK) have performed compared to their sector so far this year.
zc:7780089585217762799
0
https://www.zacks.com/stock/news/2248016/dexcom-dxcm-upgraded-to-buy-what-does-it-mean-for-the-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2248016
Mar 29, 2024 - DexCom (DXCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
zc:-4123249067025013298
0
https://www.zacks.com/stock/news/2262800/dexcom-dxcm-q1-earnings-how-key-metrics-compare-to-wall-street-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2262800
Apr 25, 2024 - While the top- and bottom-line numbers for DexCom (DXCM) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
zc:-2205232938289224993
0